Pages that link to "Q36072382"
Jump to navigation
Jump to search
The following pages link to In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). (Q36072382):
Displaying 50 items.
- Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability (Q24628212) (← links)
- Two-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase (Q24652663) (← links)
- An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014 (Q26771734) (← links)
- Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors (Q26777448) (← links)
- An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients (Q26827791) (← links)
- Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor (Q26830730) (← links)
- Current perspectives on HIV-1 antiretroviral drug resistance (Q26852626) (← links)
- HIV-1 Reverse Transcriptase Structure with RNase H Inhibitor Dihydroxy Benzoyl Naphthyl Hydrazone Bound at a Novel Site (Q27640888) (← links)
- High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations (Q27649731) (← links)
- Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design (Q27651402) (← links)
- Crystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding Pocket (Q27667348) (← links)
- A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants (Q27675380) (← links)
- Detecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-ray Crystallographic Fragment Screening (Q27675974) (← links)
- Extension into the entrance channel of HIV-1 reverse transcriptase—Crystallography and enhanced solubility (Q27679282) (← links)
- Picomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl Group (Q27680431) (← links)
- A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase (Q27683249) (← links)
- Approved Antiviral Drugs over the Past 50 Years (Q27755387) (← links)
- HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate (Q28250395) (← links)
- The design of drugs for HIV and HCV (Q28259321) (← links)
- Colloid formation by drugs in simulated intestinal fluid (Q30494603) (← links)
- Parameterization of an effective potential for protein-ligand binding from host-guest affinity data. (Q30986053) (← links)
- The multiple roles of computational chemistry in fragment-based drug design (Q33469695) (← links)
- Drug interactions with new and investigational antiretrovirals (Q33801821) (← links)
- Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation (Q33850152) (← links)
- Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition (Q33896402) (← links)
- HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. (Q33900441) (← links)
- Expanding the Antimalarial Drug Arsenal-Now, But How? (Q33916111) (← links)
- Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors (Q33996952) (← links)
- Large scale affinity calculations of cyclodextrin host-guest complexes: Understanding the role of reorganization in the molecular recognition process. (Q34065083) (← links)
- Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors (Q34303603) (← links)
- Recent highlights in the development of new antiviral drugs (Q34446169) (← links)
- Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers (Q34519713) (← links)
- Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme (Q34674575) (← links)
- Novel HIV-1 reverse transcriptase inhibitors. (Q34756615) (← links)
- Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials (Q35091523) (← links)
- Efficient Discovery of Potent Anti-HIV Agents Targeting the Tyr181Cys Variant of HIV Reverse Transcriptase (Q35243844) (← links)
- Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings (Q35557326) (← links)
- Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014 (Q35628276) (← links)
- Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents (Q35673318) (← links)
- Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase (Q35753013) (← links)
- Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity (Q35763192) (← links)
- New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir. (Q35939695) (← links)
- Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines (Q36018903) (← links)
- Role of Ligand Reorganization and Conformational Restraints on the Binding Free Energies of DAPY Non-Nucleoside Inhibitors to HIV Reverse Transcriptase (Q36029898) (← links)
- Emerging anti-HIV drugs (Q36150601) (← links)
- Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase (Q36167147) (← links)
- Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase (Q36172087) (← links)
- Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase (Q36290753) (← links)
- Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. (Q36292585) (← links)
- Biochemical mechanism of HIV-1 resistance to rilpivirine (Q36368294) (← links)